BioVie, Inc. (BIVI)
Last updated: 2026-10-24 20:02:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
BioVie, Inc. (BIVI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.25, with a market capitalization of $11.11M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.82 to $3.79. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$11.11M | |
$1.28 | |
$4,609.77 | |
$0.82 | |
$1.28 | |
140.48K | |
4.66M | |
-- | |
$3.79 | |
$0.82 | |
-- | |
-- |
BioVie, Inc. (BIVI) Latest Closing Stock Price
BioVie, Inc. (BIVI) last closed at $1.28 as of 2026-10-23 21:15:00, unchanged from the previous close of $1.28.
During the latest regular trading session, BIVI traded between $0.82 and $4,609.77, with a volume of 140.48K shares. The closing price was near the lower end and near the lower end of its 52-week range.
BioVie, Inc. (BIVI) 7-Day Stock Price Change
Over the past seven days, BioVie, Inc. (BIVI) moved from $1.13 to $1.25, representing a gain of 10.62% ($0.12).
The stock traded between $1.12 and $1.45 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 191.80 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
BIVI 52-Week Price Position
Position in Range: 14.5%
BIVI is currently trading at $1.25, placing it 14.5% of the way from its 52-week low of $0.82 to its 52-week high of $3.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is BioVie, Inc. (BIVI)?
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
BioVie, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 13 |
| Exchange | NASDAQ |
| Company Website |
How to Buy BioVie, Inc. (BIVI) Stock on MEXC
Eligible investors can buy real shares of BioVie, Inc. (BIVI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is BioVie, Inc. (BIVI) stock price today?
2.Is BIVI stock going up or down today?
3.What is BIVI pre-market price?
4.What is BIVI after-hours price?
5.Is BIVI stock trading now?
6.Where does BIVI sit relative to its 52-week high and low?
7.What sector is BioVie, Inc. in?
8.What is BioVie, Inc.'s market capitalization and where is it listed?
9.How is BIVI valued in terms of P/E ratio and EPS?
10.Does BioVie, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
BIVI Stock Calculator
Estimate the value between BIVI shares and USD.
BIVI Shares to USD
1.00 BIVI shares = 1.25 USD
Calculations are estimates based on the latest available price and are for reference only.


